Brian J. Lipworth
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Brian J. Lipworth has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
Peter A. Williamson
Asthma and Allergy Research Group, Division of Cardiovascular and Diabetes Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee, Scotland, U.K.
11 shared publicationsPhilip M. Short
Asthma and Allergy Research Group, University of Dundee, Dundee, Scotland
10 shared publicationsKarine L. Clearie
Asthma and Allergy Research Group, Ninewells Hospital and Medical School, University of Dundee, Dundee
3 shared publicationsWilliam J. Anderson
Asthma and Allergy Research Group, University of Dundee, Dundee, Scotland
3 shared publications- Andrew M. Wilson
University of East Anglia
2 shared publications Erika J Sims
2 shared publications
Latest Publications
- 1 May 2014
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 112 (5) , 475-476
Influence of β2-adrenoceptor 16 genotype on propranolol-induced bronchoconstriction in patients with persistent asthma
- 1 May 2014
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 112 (5) , 475-476
Influence of β2-adrenoceptor 16 genotype on propranolol-induced bronchoconstriction in patients with persistent asthma
- 9 September 2013
- Published by Portland Press Ltd. in Clinical Science
- Vol. 126 (1) , 75-83
Proof-of-concept evaluation of trough airway hyper-responsiveness following regular racemic or levosalbutamol in genotype-stratified steroid-treated persistent asthmatic patients
Asthmatic patients receiving ICSs (inhaled corticosteroids) may take frequent add-on therapy with salbutamol despite on-demand prescription. Frequent salbutamol use can be detrimental in asthma. The isomeric formulation of salbutamol and the B2ADR (β2 adrenoceptor) 16 genotype may also influence this phenomenon. We performed a randomized, double-blind, placebo-controlled, triple crossover, proof of concept trial comparing 2 weeks of regular therapy with inhaled racemic salbutamol [200 μg q.i.d. (four times daily)], levosalbutamol (100 μg q.i.d.) or placebo on trough methacholine PC20 [provocative concentration causing 20% fall in FEV1 (forced expiratory volume in 1 s)] 6 h post-dose (the primary outcome) in 30 persistent asthmatic patients (15 who were Arg16 homozygous and 15 who were Gly16 homozygous) all receiving ICSs. There was no worsening of AHR (airway hyper-responsiveness) at trough to methacholine after 2 weeks regular exposure to either racemic (P=0.53) or levosalbutamol (P=0.84) compared with placebo, nor between genotypes–as dd (doubling dilution) difference in methacholine PC20 from placebo [salbutamol/Arg16=0.36 dd [95% CI (confidence interval), −0.43, 1.15]; salbutamol/Gly16=0.01 dd (95% CI, −0.47, 0.49); levosalbutamol/Arg16=−0.01 dd (95% CI, −0.89, 0.87); and levosalbutamol/Gly16=0.28 dd (95% CI, −0.22, 0.77)]. Both active treatments improved morning PEF (peak expiratory flow) in Gly16 (P=0.04 overall) but not Arg16 (P=0.50 overall) patients, whereas evening PEF improved in both Gly16 (P<0.001 overall) and Arg16 (P=0.006 overall) patients. In conclusion, the regular exposure to either racemic or levosalbutamol for 2 weeks added to ICSs did not cause worsening of AHR at trough compared with placebo; with no difference seen between B2ADR 16 genotypes.
- 9 September 2013
- Published by Portland Press Ltd. in Clinical Science
- Vol. 126 (1) , 75-83
Proof-of-concept evaluation of trough airway hyper-responsiveness following regular racemic or levosalbutamol in genotype-stratified steroid-treated persistent asthmatic patients
Asthmatic patients receiving ICSs (inhaled corticosteroids) may take frequent add-on therapy with salbutamol despite on-demand prescription. Frequent salbutamol use can be detrimental in asthma. The isomeric formulation of salbutamol and the B2ADR (β2 adrenoceptor) 16 genotype may also influence this phenomenon. We performed a randomized, double-blind, placebo-controlled, triple crossover, proof of concept trial comparing 2 weeks of regular therapy with inhaled racemic salbutamol [200 μg q.i.d. (four times daily)], levosalbutamol (100 μg q.i.d.) or placebo on trough methacholine PC20 [provocative concentration causing 20% fall in FEV1 (forced expiratory volume in 1 s)] 6 h post-dose (the primary outcome) in 30 persistent asthmatic patients (15 who were Arg16 homozygous and 15 who were Gly16 homozygous) all receiving ICSs. There was no worsening of AHR (airway hyper-responsiveness) at trough to methacholine after 2 weeks regular exposure to either racemic (P=0.53) or levosalbutamol (P=0.84) compared with placebo, nor between genotypes–as dd (doubling dilution) difference in methacholine PC20 from placebo [salbutamol/Arg16=0.36 dd [95% CI (confidence interval), −0.43, 1.15]; salbutamol/Gly16=0.01 dd (95% CI, −0.47, 0.49); levosalbutamol/Arg16=−0.01 dd (95% CI, −0.89, 0.87); and levosalbutamol/Gly16=0.28 dd (95% CI, −0.22, 0.77)]. Both active treatments improved morning PEF (peak expiratory flow) in Gly16 (P=0.04 overall) but not Arg16 (P=0.50 overall) patients, whereas evening PEF improved in both Gly16 (P<0.001 overall) and Arg16 (P=0.006 overall) patients. In conclusion, the regular exposure to either racemic or levosalbutamol for 2 weeks added to ICSs did not cause worsening of AHR at trough compared with placebo; with no difference seen between B2ADR 16 genotypes.
- 14 December 2012
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 75 (1) , 93-102
Inhaled and systemic corticosteroid response in severe asthma assessed by alveolar nitric oxide: a randomized crossover pilot study of add‐on therapy
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• Extra fine inhaled corticosteroid formulations such as HFA beclomethasone may be used to target the small airways in asthma. However, it is unclear which outcome measures may detect such small airways effects in patients with severe asthma.WHAT THIS STUDY ADDS• The alveolar fraction of exhaled nitric oxide is not a sensitive outcome measure for following effects of extra fine particle inhaled beclomethasone in severe asthma. However there were significant effects on nitric oxide fractions measured at 50 ml s−1 and bronchial flux with the extra fine formulation, which did not produce significant cortisol suppression.AIMS Alveolar nitric oxide (CANO) is a potential biomarker of small airway inflammation. We investigated effects on CANO of the addition of coarse and fine particle inhaled corticosteroids to standard therapy in severe asthma.METHODS Severe asthmatics taking ≥1600 µg day−1 budesonide or equivalent performed a randomized open‐label crossover study. Subjects with FEV1 < 80%, gas trapping and CANO≥2 ppb entered a 6 week dose‐ramp run‐in of fluticasone/salmeterol(FPSM) 250/50 µg twice daily for 3 weeks, then 500/50 µg twice daily for 3 weeks. Patients then received additional HFA‐beclomethasone diproprionate (BDP) 200 µg twice daily or FP 250 µg twice daily for 3 weeks in a crossover. Participants then received prednisolone(PRED) 25 mg day−1 for 1 week. Nitric oxide, lung function, mannitol challenge, systemic inflammatory markers and urinary cortisol were measured.RESULTS Fifteen completed per protocol: mean (SD) age 51 (12) years, FEV1 58 (13)% predicted, residual volume 193 (100)% predicted and mannitolPD10 177 (2.8) µg. There was no significant difference between FPSM and add‐on therapy for CANO. FPSM/BDP and FPSM/PRED suppressed broncial flux (JawNO) and FENO compared with FPSM alone, but there was no significant difference between FPSM/BDP and FPSM/FP. ECP, e‐selectin and ICAM‐1 were suppressed by FPSM/PRED compared with FPSM and FPSM/FP but not FPSM/BDP. Plasma cortisol was significantly suppressed by FPSM/PRED.CONCLUSION In severe asthma, CANO is insensitive to changes in dose and delivery of inhaled corticosteroids and is not suppressed by systemic corticosteroids. Additional inhaled HFA‐BDP reduced FENO and JawNO without adrenal suppression. There was a trend to reduction in FENO and JawNO with additional FP but this did not reach statistical significance. PRED reduced FENO and JawNO with suppression of systemic inflammatory markers and urinary cortisol.
- 14 December 2012
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 75 (1) , 93-102
Inhaled and systemic corticosteroid response in severe asthma assessed by alveolar nitric oxide: a randomized crossover pilot study of add‐on therapy
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• Extra fine inhaled corticosteroid formulations such as HFA beclomethasone may be used to target the small airways in asthma. However, it is unclear which outcome measures may detect such small airways effects in patients with severe asthma.WHAT THIS STUDY ADDS• The alveolar fraction of exhaled nitric oxide is not a sensitive outcome measure for following effects of extra fine particle inhaled beclomethasone in severe asthma. However there were significant effects on nitric oxide fractions measured at 50 ml s−1 and bronchial flux with the extra fine formulation, which did not produce significant cortisol suppression.AIMS Alveolar nitric oxide (CANO) is a potential biomarker of small airway inflammation. We investigated effects on CANO of the addition of coarse and fine particle inhaled corticosteroids to standard therapy in severe asthma.METHODS Severe asthmatics taking ≥1600 µg day−1 budesonide or equivalent performed a randomized open‐label crossover study. Subjects with FEV1 < 80%, gas trapping and CANO≥2 ppb entered a 6 week dose‐ramp run‐in of fluticasone/salmeterol(FPSM) 250/50 µg twice daily for 3 weeks, then 500/50 µg twice daily for 3 weeks. Patients then received additional HFA‐beclomethasone diproprionate (BDP) 200 µg twice daily or FP 250 µg twice daily for 3 weeks in a crossover. Participants then received prednisolone(PRED) 25 mg day−1 for 1 week. Nitric oxide, lung function, mannitol challenge, systemic inflammatory markers and urinary cortisol were measured.RESULTS Fifteen completed per protocol: mean (SD) age 51 (12) years, FEV1 58 (13)% predicted, residual volume 193 (100)% predicted and mannitolPD10 177 (2.8) µg. There was no significant difference between FPSM and add‐on therapy for CANO. FPSM/BDP and FPSM/PRED suppressed broncial flux (JawNO) and FENO compared with FPSM alone, but there was no significant difference between FPSM/BDP and FPSM/FP. ECP, e‐selectin and ICAM‐1 were suppressed by FPSM/PRED compared with FPSM and FPSM/FP but not FPSM/BDP. Plasma cortisol was significantly suppressed by FPSM/PRED.CONCLUSION In severe asthma, CANO is insensitive to changes in dose and delivery of inhaled corticosteroids and is not suppressed by systemic corticosteroids. Additional inhaled HFA‐BDP reduced FENO and JawNO without adrenal suppression. There was a trend to reduction in FENO and JawNO with additional FP but this did not reach statistical significance. PRED reduced FENO and JawNO with suppression of systemic inflammatory markers and urinary cortisol.
- 9 June 2012
- Published by Springer Nature in Lung
- Vol. 190 (5) , 513-521
Relationship of Mannitol Challenge to Methacholine Challenge and Inflammatory Markers in Persistent Asthmatics Receiving Inhaled Corticosteroids
Background Mannitol is a novel osmotic indirect bronchial challenge agent used to aid asthma diagnosis and management and is thought to reflect underlying inflammatory processes in asthma. Our objective was to evaluate relationships between mannitol airway hyperresponsiveness (AHR) and other measures of airway inflammation as well as direct-acting methacholine challenge in persistent asthmatics receiving inhaled corticosteroids. Methods We analysed screening data of mild to moderate persistent asthmatics, all receiving inhaled corticosteroids (ICS), who had mannitol and/or methacholine challenges, fractional exhaled nitric oxide (FeNO), and salivary eosinophilic cationic protein (ECP) performed as part of the same screen. Mannitol AHR was grouped by PD10 (cumulative provocative dose required to produce a 10 % fall in FEV1): mild (315–635 mg), moderate (75–315 mg), and severe (0–75 mg). FeNO groups were low ( 50 ppb) and methacholine PC20 (provocative concentration of methacholine required to cause a 20 % fall in FEV1) groups were mild (2–8 mg/ml), moderate (0.5–2 mg/ml), and severe (0–0.5 mg/ml). Results Mannitol PD10 groups were significantly different overall for FeNO (p = 0.023): 43 % higher in the severe vs. the mild group. There was a significant overall difference for methacholine PC20 (p = 0.006): a 2.1 doubling dilution difference between severe vs. mild mannitol groups. FeNO groups were significantly different overall for mannitol PD10 (p = 0.01) and methacholine PC20 (p = 0.029). Methacholine PC20 groups were significantly different overall for mannitol PD10 (p < 0.001) and FeNO (p = 0.005). No significant differences were found across any groups for salivary ECP, FEV1 % predicted, or ICS dose. Mannitol PD10, methacholine PC20, and FeNO as continuous variables all correlated with each other. Conclusions Mannitol challenge reflects underlying inflammation using FeNO and direct AHR using methacholine. Thus, mannitol may be a useful screening tool for the assessment of asthmatic patients receiving inhaled corticosteroids.
- 9 June 2012
- Published by Springer Nature in Lung
- Vol. 190 (5) , 513-521
Relationship of Mannitol Challenge to Methacholine Challenge and Inflammatory Markers in Persistent Asthmatics Receiving Inhaled Corticosteroids
Background Mannitol is a novel osmotic indirect bronchial challenge agent used to aid asthma diagnosis and management and is thought to reflect underlying inflammatory processes in asthma. Our objective was to evaluate relationships between mannitol airway hyperresponsiveness (AHR) and other measures of airway inflammation as well as direct-acting methacholine challenge in persistent asthmatics receiving inhaled corticosteroids. Methods We analysed screening data of mild to moderate persistent asthmatics, all receiving inhaled corticosteroids (ICS), who had mannitol and/or methacholine challenges, fractional exhaled nitric oxide (FeNO), and salivary eosinophilic cationic protein (ECP) performed as part of the same screen. Mannitol AHR was grouped by PD10 (cumulative provocative dose required to produce a 10 % fall in FEV1): mild (315–635 mg), moderate (75–315 mg), and severe (0–75 mg). FeNO groups were low ( 50 ppb) and methacholine PC20 (provocative concentration of methacholine required to cause a 20 % fall in FEV1) groups were mild (2–8 mg/ml), moderate (0.5–2 mg/ml), and severe (0–0.5 mg/ml). Results Mannitol PD10 groups were significantly different overall for FeNO (p = 0.023): 43 % higher in the severe vs. the mild group. There was a significant overall difference for methacholine PC20 (p = 0.006): a 2.1 doubling dilution difference between severe vs. mild mannitol groups. FeNO groups were significantly different overall for mannitol PD10 (p = 0.01) and methacholine PC20 (p = 0.029). Methacholine PC20 groups were significantly different overall for mannitol PD10 (p < 0.001) and FeNO (p = 0.005). No significant differences were found across any groups for salivary ECP, FEV1 % predicted, or ICS dose. Mannitol PD10, methacholine PC20, and FeNO as continuous variables all correlated with each other. Conclusions Mannitol challenge reflects underlying inflammation using FeNO and direct AHR using methacholine. Thus, mannitol may be a useful screening tool for the assessment of asthmatic patients receiving inhaled corticosteroids.
- 5 April 2012
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 73 (5) , 717-726
Effects of hydrocortisone on acute β-adrenoceptor blocker and histamine induced bronchoconstriction
AIMS beta-adrenoceptor blockers are avoided in asthma due to concerns of bronchoconstriction. We investigated the safety of acute exposure to propranolol in asthmatics, sequentially challenged with histamine to mimic an asthma exacerbation and evaluated the role of intravenous hydrocortisone in potentiating salbutamol reversibility. METHODS Persistent atopic asthmatics, requiring <= 1000 mg day(-1) budesonide, performed a randomized double-blind placebo-controlled crossover study. Following 10 mg or 20 mg of oral propranolol, patients received 400 mg intravenous hydrocortisone or placebo, followed by histamine challenge with nebulized salbutamol 5mg and ipratropium 500 mg recovery. RESULTS Thirteen patients completed per protocol. Hydrocortisone did not potentiate salbutamol recovery post propranolol and histamine challenge vs. placebo (mean difference in FEV1 0.04 ml, 95% CI -0.07, 0.15, P = 0.417). beta-adrenoceptor blocker induced bronchoconstriction was demonstrated by spirometry and impulse oscillometry. For the placebo visit, FEV1 fell 4.7% 2 hours post propranolol (95% CI 1.8, 7.5, P = 0.008) whilst total airway resistance (R5%) increased 31.3% (95% CI 15.6, 47.0, P = 0.04). On both visits FEV1% and R5% returned to baseline after salbutamol post histamine. CONCLUSION Nebulized salbutamol and ipratropium produced a full recovery after propranolol and histamine induced bronchoconstriction, independent of hydrocortisone use. Since the greatest risk of beta-adrenoceptor blockade is after first dose, our findings offer reassurance to those undertaking further evaluation of chronic beta-adrenoceptor blockade as a potential treatment for mild-to-moderate asthma.
- 5 April 2012
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 73 (5) , 717-726
Effects of hydrocortisone on acute β-adrenoceptor blocker and histamine induced bronchoconstriction
AIMS beta-adrenoceptor blockers are avoided in asthma due to concerns of bronchoconstriction. We investigated the safety of acute exposure to propranolol in asthmatics, sequentially challenged with histamine to mimic an asthma exacerbation and evaluated the role of intravenous hydrocortisone in potentiating salbutamol reversibility. METHODS Persistent atopic asthmatics, requiring <= 1000 mg day(-1) budesonide, performed a randomized double-blind placebo-controlled crossover study. Following 10 mg or 20 mg of oral propranolol, patients received 400 mg intravenous hydrocortisone or placebo, followed by histamine challenge with nebulized salbutamol 5mg and ipratropium 500 mg recovery. RESULTS Thirteen patients completed per protocol. Hydrocortisone did not potentiate salbutamol recovery post propranolol and histamine challenge vs. placebo (mean difference in FEV1 0.04 ml, 95% CI -0.07, 0.15, P = 0.417). beta-adrenoceptor blocker induced bronchoconstriction was demonstrated by spirometry and impulse oscillometry. For the placebo visit, FEV1 fell 4.7% 2 hours post propranolol (95% CI 1.8, 7.5, P = 0.008) whilst total airway resistance (R5%) increased 31.3% (95% CI 15.6, 47.0, P = 0.04). On both visits FEV1% and R5% returned to baseline after salbutamol post histamine. CONCLUSION Nebulized salbutamol and ipratropium produced a full recovery after propranolol and histamine induced bronchoconstriction, independent of hydrocortisone use. Since the greatest risk of beta-adrenoceptor blockade is after first dose, our findings offer reassurance to those undertaking further evaluation of chronic beta-adrenoceptor blockade as a potential treatment for mild-to-moderate asthma.
- 22 February 2012
- Published by Springer Nature in Lung
- Vol. 190 (4) , 395-401
Effects of Extra-Fine Inhaled and Oral Corticosteroids on Alveolar Nitric Oxide in COPD
Alveolar nitric oxide (CANO) has been suggested as a surrogate marker of distal airway inflammation in COPD. Coarse particle-inhaled corticosteroids (ICS) have been shown not to suppress CANO. We evaluated whether extra-fine particle size ICS (HFA-BDP) or systemic oral corticosteroids could suppress CANO in COPD. Chronic obstructive pulmonary disease (COPD) patients with a FEV1/FVC ratio NO was corrected for axial diffusion. In 16 participants, there were no significant differences seen with either dose of HFA-BDP compared with placebo. Oral prednisolone significantly reduced FENO and J’awNO but not CANO. Plasma cortisol was significantly suppressed by oral prednisolone only. Whilst CANO remains a biomarker of interest in COPD, it is not suppressed by systemic or extra-fine particle ICS. CANO is not a useful marker for monitoring response of small airway disease to therapies in COPD. The study was approved by the local Committee on Medical Research Ethics and registered on ClinicalTrials.Gov (NCT 00921921).
- 22 February 2012
- Published by Springer Nature in Lung
- Vol. 190 (4) , 395-401
Effects of Extra-Fine Inhaled and Oral Corticosteroids on Alveolar Nitric Oxide in COPD
Alveolar nitric oxide (CANO) has been suggested as a surrogate marker of distal airway inflammation in COPD. Coarse particle-inhaled corticosteroids (ICS) have been shown not to suppress CANO. We evaluated whether extra-fine particle size ICS (HFA-BDP) or systemic oral corticosteroids could suppress CANO in COPD. Chronic obstructive pulmonary disease (COPD) patients with a FEV1/FVC ratio NO was corrected for axial diffusion. In 16 participants, there were no significant differences seen with either dose of HFA-BDP compared with placebo. Oral prednisolone significantly reduced FENO and J’awNO but not CANO. Plasma cortisol was significantly suppressed by oral prednisolone only. Whilst CANO remains a biomarker of interest in COPD, it is not suppressed by systemic or extra-fine particle ICS. CANO is not a useful marker for monitoring response of small airway disease to therapies in COPD. The study was approved by the local Committee on Medical Research Ethics and registered on ClinicalTrials.Gov (NCT 00921921).